CN103720765A - Traditional Chinese medicine composition for treating diabetes and preparation method thereof - Google Patents

Traditional Chinese medicine composition for treating diabetes and preparation method thereof Download PDF

Info

Publication number
CN103720765A
CN103720765A CN201410031992.4A CN201410031992A CN103720765A CN 103720765 A CN103720765 A CN 103720765A CN 201410031992 A CN201410031992 A CN 201410031992A CN 103720765 A CN103720765 A CN 103720765A
Authority
CN
China
Prior art keywords
chinese medicine
medicine composition
diabetes
treatment
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410031992.4A
Other languages
Chinese (zh)
Other versions
CN103720765B (en
Inventor
李冬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Qing Xiao Hong Tuo Pharmaceutical Technology Development Co., Ltd.
Original Assignee
ZHUHAI BINHAI PHARMACEUTICAL BIOTECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZHUHAI BINHAI PHARMACEUTICAL BIOTECHNOLOGY Co Ltd filed Critical ZHUHAI BINHAI PHARMACEUTICAL BIOTECHNOLOGY Co Ltd
Priority to CN201410031992.4A priority Critical patent/CN103720765B/en
Priority to IE20140059A priority patent/IE20140059A1/en
Priority to GB1403996.0A priority patent/GB2522283A/en
Priority to NL2012393A priority patent/NL2012393C2/en
Publication of CN103720765A publication Critical patent/CN103720765A/en
Application granted granted Critical
Publication of CN103720765B publication Critical patent/CN103720765B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533—Leonurus (motherwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The invention aims to provide a traditional Chinese medicine composition for treating diabetes, which is significant in curative effect, short in course of treatment and high in cure rate in diabetes treatment. The traditional Chinese medicine composition for treating diabetes is characterized by comprising active components such as musk, rhizoma ligustici wallichii, motherwort, clove and fructus xanthii.

Description

A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof
Technical field
The present invention relates to the field of Chinese medicines, particularly a kind ofly can treat pharmaceutical composition of diabetes and preparation method thereof.
Background technology
Diabetes spp motherland medical science " diabetes " category, traditional Chinese medical science traditional treatment is partial to scorching the saying of the deficiency of YIN more.According to modern medicine study, often there is the fibrosis of blood capillary in islets of langerhans in glycosuria patient, and blood viscosity increases, and erythrocyte aggregation strengthens, and blood vessel wall is adhered to platelet and aggregation strengthens, and thrombin, Fibrinogen such as increase at the blood stasis pathological change.Clinically see that numb limbs and tense tendons, purple lip tongue are dark, the syndrome of blood stasis feature such as tongue limit petechia or ecchymosis, the bent, Jia of Sublingual venation stasis of blood Han are slow, thready and hesitant pulse.Therefore blood stasis is the important pathogenesis of primary disease morbidity, is also in treatment, to obtain the key point of late result.
Chinese medicine thinks, vasculopathy of the lower extremity in diabetes becomes the deficiency of both QI and YIN that belong to more, blood vessels stasis of blood plug, and acra loses supports " be the card of deficiency in origin and excess in superficiality, take deficiency of both QI and YIN as this, blood stasis pyretic toxicity is mark ", " blood stasis due to qi deficiency, yang-energy does not reach for pathogenesis key ".
Summary of the invention
Technical problem to be solved by this invention is, provide a kind of to treatment diabetes have evident in efficacy, control short treating period, Chinese medicine composition that cure rate is high.
The object of the invention is to be achieved through the following technical solutions,
A kind of Chinese medicine composition for the treatment of diabetes, Rhizoma Chuanxiong), Herba Leonuri (Latin formal name used at school Leonurus japonicus Houtt), Flos Caryophylli (latin name: Syringa oblata), Fructus Xanthii (latin name anthium sibiricum.) it is characterized in that, it comprises following active component: Moschus (latin name: Moschus), Rhizoma Chuanxiong (latin name:.The weight proportion of above-mentioned active component is: Moschus 50-500, Rhizoma Chuanxiong 50-500, Herba Leonuri 50-500, Flos Caryophylli 10-80, Fructus Xanthii 10-80.Preferred weight proportioning: Moschus 200, Rhizoma Chuanxiong 200, Herba Leonuri 150, Flos Caryophylli 60, Fructus Xanthii 60.
Another object of the present invention is, a kind of method of preparing above-mentioned Chinese medicine composition is provided.
When application, medicine of the present invention can add one or more pharmaceutically acceptable carriers as required, as diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant etc., be prepared into the dosage form needing.
Medicine provided by the invention, according to actual needs, can further be processed into the multiple dosage forms such as oral liquid, tablet, capsule, granule and injection.Above-mentioned dosage form all can be according to the conventional method preparation of pharmaceutical field.
The specific embodiment
Below in conjunction with pharmacodynamics and toxicological experiment, introduce the present invention in the effect for the treatment of diabetes, describe the present invention and specific embodiment in detail.
Embodiment 1
Accurate weighed Moschus 200g, Rhizoma Chuanxiong 200g, Herba Leonuri 150g, Flos Caryophylli 60g, Fructus Xanthii 60g rinse well with deionized water, add 3200ml deionized water, and heating extraction, after 1 hour, is emitted extracting solution; Add 2400ml deionized water, heating extraction, after 1 hour, is emitted extracting solution again; Add 2400ml deionized water, heating extraction, after 0.5 hour, is emitted extracting solution again.After three extracting liquid filterings, merge, be concentrated into 600m1, then to add concentration be that 95% ethanol makes to be 60%, precipitate 24 hours, filtration containing alcohol amount; Filtrate is recycled to 400ml, add concentration be 95% ethanol to make containing alcohol amount be 80%, precipitation, filters, and reclaims ethanol and is also concentrated into 400g, obtains Chinese medicine extraction compositions.
Embodiment 2
The preparation of 250ml injection is got embodiment 1 and is extracted compositions 10g, injects water and makes in right amount to dissolve, and adds sodium chloride 2.25g, with water for injection, adjust volume to 125ml, add appropriate injection charcoal, boil 15 minutes, let cool, filter, filtrate injects water adjustment total amount and to 250ml, regulates pH value, filtration, fill, sterilizing, packing, obtains.
Embodiment 3
Person classifies the outpatient service object of observation as according to World Health Organization (WHO) (WH0) diabetes diagnosis standard in 1985, to be diagnosed as type ii diabetes.Observe altogether 177 examples, according to different sexes, age and the course of disease, be divided into observation group's 125 examples, matched group 52 examples.In observation group's 125 examples, male 89 examples, female's 36 examples; The oldest 75 years old, minimum 29 years old, average 51 years old; The course of disease is the longest 19 years, the shortest 1 month, average 3.5 years.Wherein accompany hyperlipemia 68 examples, coronary heart disease 19 examples, hypertension 18 examples, gout 3 examples; Complicated with diabetes cerebrovascular 5 examples, diabetic foot 2 examples; Chinese medical discrimination belongs to deficiency of yin and stagnation of blood 78 examples, turbid type 33 examples of the deficiency of vital energy stasis of blood, kidney deficiency blood stasis type 14 examples.Matched group 52 examples, male 36 examples, female's 16 examples; The oldest 74 years old, minimum 30 years old, average 53 years old; The course of disease is the longest 18 years, the shortest 1.5 months, average 3 years.Wherein accompany hyperlipemia 20 examples, coronary heart disease 5 examples, hypertension 8 examples, gout 1 example; Complicated with diabetes cerebrovascular 2 examples, diabetic peripheral neuropathy 2 examples, diabetic foot 1 example.Two groups of sexes, age, course of disease comparison, learn by statistics and process there was no significant difference (P>0.05).
Matched group is strictly controlled blood glucose, blood glucose is maintained approach or reaches normal level, vitamin B12 500Lg intramuscular injection, VB11 0mg is oral with trophic nerve, 65422 injection 20mg add in 0.9% sodium chloride injection 250ml, every day 1 time, intravenous drip "
" 2 groups of 1.2.3 courses for the treatment of equal 2 weeks are 1 course for the treatment of, after 1 course for the treatment of, add up curative effect for treatment group embodiment 2 injection 250ml, every day 1 time, intravenous drip.
Curative effect judgement
Criterion of therapeutical effect is according to Chinese Chinese medicine association's diabetes (diabetes) Professional Committee working conference for the third time (in May, 1992, Shandong) criterion of therapeutical effect of formulating, drafts [1] in conjunction with < < traditional Chinese medical science disease Standardization of diagnosis and curative effect > >: effective is transference cure; Fasting glucose <6.1mmol/L, 2h-plasma glucose <8.3mmol/L.Effectively for symptom, substantially disappear; Fasting glucose <8.3mmol/L, 2h-plasma glucose <11.1mmol/L.Invalid is that symptom and lab testing are unchanged, or aggravation.3.2 therapeutic outcome observation group 125 examples, effective 92 examples, effective 25 examples, invalid 8 examples, obvious effective rate 73.6%, total effective rate 93.6%.Matched group 52 examples, effective 15 examples, effective 17 examples, invalid 20 examples, obvious effective rate 28.9%, total effective rate 61.6%.Observation group compares with matched group, learns and processes by statistics, and obvious effective rate and total effective rate all have significant difference (P<0.01).Effective case 65 examples of observation group are followed up a case by regular visits to, wherein, in 5 example 5 years, in 15 examples 3 years, in 45 examples 1 year, have no recurrence.
From above-mentioned experimental result, the medicine of being prepared by Chinese medicine composition of the present invention has significant therapeutic effect to diabetes.Embodiment 4
According to weight proportion, get Moschus 500g, Rhizoma Chuanxiong 500g, Herba Leonuri 50g, Flos Caryophylli 10g, Fructus Xanthii 10g, PEG-4000 5g, Tween-80 0.5g.Be ready to after raw material, carbon dioxide supercritical fluid extraction or water vapour distillation volatile oil for recipe quantity medicine, add Borneolum Syntheticum, adjuvant substrate, makes drop pill.
Embodiment 5
According to weight proportion, get Moschus 50g, Rhizoma Chuanxiong 50g, Herba Leonuri 500g, Flos Caryophylli 80g, Fructus Xanthii 80g, Tween-80 3.5g.Be ready to after raw material, get carbon dioxide supercritical fluid extraction or water vapour distillation volatile oil for recipe quantity medicine, add Borneolum Syntheticum, adjuvant substrate, make gel.
Embodiment 6
According to weight proportion, get Rhizoma Acori Graminei Moschus 300g, Rhizoma Chuanxiong 300g, Herba Leonuri 150g, Flos Caryophylli 50g, Fructus Xanthii 50g, Tween-80 1.74g.Be ready to after raw material, medicinal carbon dioxide supercritical fluid extraction or water vapour distillation volatile oil in recipe quantity, add Borneolum Syntheticum, adjuvant substrate, granulation.

Claims (5)

1. a Chinese medicine composition for the treatment of diabetes, is characterized in that, it comprises following active component: Moschus, Rhizoma Chuanxiong, Herba Leonuri, Flos Caryophylli and Fructus Xanthii.
2. the Chinese medicine composition for the treatment of diabetes according to claim 1, is characterized in that, the weight proportion of described active component is: Moschus 50～500, Rhizoma Chuanxiong 50～500, Herba Leonuri 50～500, Flos Caryophylli 10～80, Fructus Xanthii 10～80.
3. the Chinese medicine composition for the treatment of diabetes according to claim 2, is characterized in that, the weight proportion of described active component is: Moschus 200, Rhizoma Chuanxiong 200, Herba Leonuri 150, Flos Caryophylli 60, Fructus Xanthii 60.
4. according to the Chinese medicine composition of the treatment diabetes described in claim 1-3 any one, it is characterized in that, it can add one or more pharmaceutically acceptable carriers, is prepared into the dosage form needing.
5. the Chinese medicine composition for the treatment of diabetes according to claim 4, it is characterized in that, described pharmaceutically acceptable carrier is diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier or lubricant.
CN201410031992.4A 2014-01-16 2014-01-16 Traditional Chinese medicine composition for treating diabetes and preparation method thereof Expired - Fee Related CN103720765B (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201410031992.4A CN103720765B (en) 2014-01-16 2014-01-16 Traditional Chinese medicine composition for treating diabetes and preparation method thereof
IE20140059A IE20140059A1 (en) 2014-01-16 2014-03-06 Traditional Chinese medicine composition for the treatment of diabetes
GB1403996.0A GB2522283A (en) 2014-01-16 2014-03-06 Traditional chinese medicine composition for the treatment of diabetes
NL2012393A NL2012393C2 (en) 2014-01-16 2014-03-11 Traditional chinese medicine composition for the treatment of diabetes.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410031992.4A CN103720765B (en) 2014-01-16 2014-01-16 Traditional Chinese medicine composition for treating diabetes and preparation method thereof

Publications (2)

Publication Number Publication Date
CN103720765A true CN103720765A (en) 2014-04-16
CN103720765B CN103720765B (en) 2017-01-11

Family

ID=50445227

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410031992.4A Expired - Fee Related CN103720765B (en) 2014-01-16 2014-01-16 Traditional Chinese medicine composition for treating diabetes and preparation method thereof

Country Status (4)

Country Link
CN (1) CN103720765B (en)
GB (1) GB2522283A (en)
IE (1) IE20140059A1 (en)
NL (1) NL2012393C2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104784237A (en) * 2015-04-08 2015-07-22 吉林农业大学 Application of Italian cocklebur in preparation of alpha-glucosidase inhibitor
CN106075209A (en) * 2016-07-12 2016-11-09 佛山杰致信息科技有限公司 A kind of compositions treating diabetes
KR20200045206A (en) * 2018-10-22 2020-05-04 주식회사 한웅 mixture containing musk rat musk having anti-diabetic activity and preparation thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111454774A (en) * 2020-04-26 2020-07-28 五邑大学 Method for extracting plant essential oil with hypoglycemic activity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07316582A (en) * 1994-05-21 1995-12-05 Shiseido Co Ltd Sleep-inducing perfume composition
JPH0923849A (en) * 1995-07-14 1997-01-28 Moritani Kenko Shokuhin Kk Health food for quiet sleep
CN1628845A (en) * 2003-12-17 2005-06-22 昆明紫健生物技术有限公司 Compound medicinal formulation with bioactivity
CN101549096A (en) * 2009-04-19 2009-10-07 丁家轩 Chinese medicine particles for treating diabetes
CN101766699A (en) * 2006-03-27 2010-07-07 深圳市生物谷科技有限公司 Medicinal combination containing musk

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922263A (en) * 1974-12-16 1975-11-25 Univ Mississippi Hypoglycemic compound and method of preparing
CN101766705B (en) * 2006-03-27 2011-08-03 深圳市金沙江投资有限公司 Medicinal combination containing borneol and musk
CN102948892A (en) * 2011-08-30 2013-03-06 王新建 Leonurus heterophyllus sweet blood glucose reducing beverage and preparing method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07316582A (en) * 1994-05-21 1995-12-05 Shiseido Co Ltd Sleep-inducing perfume composition
JPH0923849A (en) * 1995-07-14 1997-01-28 Moritani Kenko Shokuhin Kk Health food for quiet sleep
CN1628845A (en) * 2003-12-17 2005-06-22 昆明紫健生物技术有限公司 Compound medicinal formulation with bioactivity
CN101766699A (en) * 2006-03-27 2010-07-07 深圳市生物谷科技有限公司 Medicinal combination containing musk
CN101549096A (en) * 2009-04-19 2009-10-07 丁家轩 Chinese medicine particles for treating diabetes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
东明县人民医院刘楼分院: "中医中药治疗268例糖尿病疗效观察", 《山东中医杂志》, no. 5, 31 December 1984 (1984-12-31), pages 23 - 26 *
张蕾，等: "丁香对胰岛素信号通路的影响及2型糖尿病降糖机制的研究", 《长春中医药大学学报》, vol. 29, no. 4, 31 August 2013 (2013-08-31), pages 719 - 722 *
田双彦，等: "益母草临床应用研究综述", 《临床误诊误治》, vol. 21, no. 7, 31 December 2008 (2008-12-31), pages 73 - 75 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104784237A (en) * 2015-04-08 2015-07-22 吉林农业大学 Application of Italian cocklebur in preparation of alpha-glucosidase inhibitor
CN106075209A (en) * 2016-07-12 2016-11-09 佛山杰致信息科技有限公司 A kind of compositions treating diabetes
KR20200045206A (en) * 2018-10-22 2020-05-04 주식회사 한웅 mixture containing musk rat musk having anti-diabetic activity and preparation thereof

Also Published As

Publication number Publication date
GB2522283A (en) 2015-07-22
CN103720765B (en) 2017-01-11
IE20140059A1 (en) 2014-07-16
GB201403996D0 (en) 2014-04-23
NL2012393C2 (en) 2015-07-20

Similar Documents

Publication Publication Date Title
CN101716214A (en) Medical composition containing dandelion extract as well as novel application and preparation method thereof
CN103720765A (en) Traditional Chinese medicine composition for treating diabetes and preparation method thereof
CN104338010A (en) Traditional Chinese medicine composition for treatment of type 2 diabetes
CN102631526A (en) Chinese medicinal composition for treating diabetes mellitus
CN109260397A (en) A kind of Chinese medicine composition for treating Vascular retinopathy
CN105125885B (en) It is a kind of to be used to prevent Chinese medicine composition of diabetes and preparation method thereof
CN108450597A (en) A kind of plant compound tea beverage
CN103520684B (en) Traditional Chinese medicine compound for reducing blood sugar
CN103536879B (en) A kind of pharmaceutical composition and preparation method for the treatment of diabetes
CN107648397B (en) Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof
CN104922445B (en) A kind of Traditional Chinese medicine compound composition and the preparation method and application thereof with treatment heart failure effect
CN108079184B (en) Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diabetic retinopathy
CN107737173A (en) A kind of Chinese medicine preparation for treating diabete peripheral herve pathology and preparation method thereof
CN1857531A (en) Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy
CN104288231A (en) Medicine for treating refractory epilepsy
CN100542576C (en) A kind of pharmaceutical composition for the treatment of soft tissue injury and dysmenorrhea and preparation method thereof
CN101020010A (en) Oral liquid for treating common cold heat
CN100446800C (en) Chinese traditional medicine composition
CN1331500C (en) Chinese medicine for treating ocular funcus hemorrhage caused by yin deficiency, liver sthenia, heat impairing collaterals and preparation method
CN105031546A (en) Traditional Chinese medicine for preventing and treating diabetic retinopathy and preparation method of traditional Chinese medicine
CN105998431A (en) Traditional Chinese medicine composition for treating cataract and preparation method thereof
CN100435825C (en) Application of anemarrhena extract in preparing mediciation for preventing and curing abnormal rapidity heart rate and essential hyperension
KR20230126459A (en) A traditional chinese medicine
CN102451248B (en) Application of traditional Chinese medicine composition in preparation of medicament for treating diabetic neuropathy
CN111544521A (en) Traditional Chinese medicine composition for cataract

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20181025

Address after: 100123 Chaoyang District, Beijing, Ping Yuan Township, 1 homes, 1 homes, 5 homes, 5133 rooms.

Patentee after: Beijing Qing Xiao Hong Tuo Pharmaceutical Technology Development Co., Ltd.

Address before: 519020 Lingnan Road, Xiangzhou District, Zhuhai, Guangdong 68-1065

Patentee before: ZHUHAI BINHAI PHARMACEUTICAL BIOTECHNOLOGY CO., LTD.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170111

Termination date: 20200116

CF01 Termination of patent right due to non-payment of annual fee